Videos

Dr. Christophe Arbet-Engels explains how empagliflozin could be dosed once approved. and that the highest dose showed the most benefit in trials with reductions in weight and blood pressure. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels continues his discussion of the potential for combining the SGLT-2 inhibitor empagliflozin with other drugs down the road, and that they will certainly be exploring these otpions.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels explains that Boehringer Ingelheim will also be submitting empagliflozin internationally, and certainly in the EU, and that they will also look carefully at all possibilities to submit the drug to other international authorities. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim …

Dr. Christophe Arbet-Engels answer the question, “Do the Swiss get diabetes?” and, on a more serious note, explains that they are exploring different options for different patient populations to find the best treatment possible for each individual patient.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, …

Dr. Christophe Arbet-Engels talks about some of the diabetes drugs in Boehringer Ingelheim’s pipeline including several compounds with liagliptin which BI is continuing to study and expand their knowledge of. They have looked at data in the past on African Americans and are now examining data of the drug’s efficacy in …

Dr. Christophe Arbet-Engels talks about the empagliflozin studies and the ongoing safety program to identify any safety and side-effect concerns. However, despite reported potential urinary tract and genital infection issues, the large majority of patients of the study's 14,000 participants didn't observe any of these effects.

Dr. Christophe Arbet-Engels talks about how empagliflozin differs from other SGLT-2 inhibitors already on the market such as canagliflozin and dapagliflozin, stating that empagliflozin is “very specific” to its target, but hasn’t yet been compared to the others so it is too early to tell what other differences there might be. …

  Robert E. Ratner, MD, talks about the best way to screen for prediabetes, and the importance of balancing convenience and specificity.  

Robert E. Ratner, MD, talks about how the ADA is working to identify prediabetes and delay the onset as much as possible of diabetes. He explains that screening is extremely important and that this process also provides an opportunity for intervention. He also emphasizes that lifestyle modification is the first step …

Dr. Christophe Arbet-Engels explains how Eli Lilly and Boehringer Ingelheim have created and alliance and what that means in terms of promotion.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources